Startup wants to bring back Vioxx for hemophilia joint pain

November 21, 2017 by Linda A. Johnson
Startup could bring back Vioxx for hemophilia
In this Wednesday, Nov. 15, 2017, photo, Brad Sippy, chief executive officer of Tremeau Pharmaceuticals, Inc., stands for a portrait in Cambridge, Mass. Tremeau Pharmaceuticals, Inc., is a small startup trying to bring the recalled painkiller Vioxx back to the market. They are seeking FDA approval for patients with hemophilia with severe pain, but once on the market, doctors could go back to prescribing it to anyone with pain. (AP Photo/Steven Senne)

Could there be a second life for the once-popular arthritis pill Vioxx? A startup pharmaceutical company hopes so.

Merck & Co. voluntarily pulled the blockbuster drug in 2004 amid evidence that it doubled the chances of having a heart attack or stroke.

Now tiny Tremeau Pharmaceuticals is working to bring it back, to treat severe joint pain caused by the bleeding disorder hemophilia. That's for far fewer patients than the millions who took Vioxx pills for arthritis and other chronic pain—but if it's approved doctors could again legally prescribe it to anyone.

Many hemophilia patients rely on opioid painkillers because nearly every other pain reliever increases the risk of internal bleeding. Considerable research shows Vioxx doesn't do that.

"It seemed to me that there was a huge unmet medical need" for these patients, Brad Sippy, Tremeau's chief executive, told The Associated Press. He put together a plan and co-founded Tremeau last year to develop nonopioid pain treatments for rare diseases.

A longtime pharmaceutical marketing executive, Sippy worked at Merck during the Vioxx era and helped with its recall from pharmacy shelves. He also knew the final patent protecting Vioxx's monopoly was expiring this fall.

When it stopped making Vioxx, Merck was facing thousands of lawsuits from people claiming the drug caused their heart attacks or strokes. Merck's own research showed the drug doubled those risks, but lawyers for patients claimed the company downplayed or concealed that. Merck initially fought the lawsuits but in 2007 agreed to a $4.85 billion settlement.

If Tremeau gets approval in a few years to start selling rofecoxib, the chemical name for Vioxx, doctors could prescribe it to other people with garden-variety chronic pain. Tremeau wouldn't be able to legally promote those unapproved uses, but some patients likely would want it. Vioxx was so effective that some users hoarded it after Merck took it off market.

"I know a lot of people who swore by Vioxx," said analyst Steve Brozak, president of WBB Securities. "Repurposing this for the hemophilia community is particularly brilliant."

Startup could bring back Vioxx for hemophilia
In this Wednesday, Nov. 15, 2017, photo, Brad Sippy, chief executive officer of Tremeau Pharmaceuticals, Inc., stands for a portrait, in Cambridge, Mass. Tremeau Pharmaceuticals, Inc., is a small startup trying to bring the recalled painkiller Vioxx back to the market. They are seeking FDA approval for patients with hemophilia with severe pain, but once on the market, doctors could go back to prescribing it to anyone with pain. (AP Photo/Steven Senne)

Dr. Steven Stanos, president of the American Academy of Pain Management, a professional group for pain specialists, said it made sense to try Vioxx for hemophilia joint pain.

"Vioxx was very potent," he said.

The drug would still carry a strong warning about heart attack and stroke risks. Doctors would have to balance its pain benefit against each patient's risks, Stanos said.

On Tuesday, Tremeau announced that the Food and Drug Administration recently handed it an endorsement of sorts: an orphan drug designation. That's for disorders affecting fewer than 200,000 Americans, and comes with benefits, including tax credits on testing costs and a free FDA review.

Still, it's no slam-dunk. Sippy said the Cambridge, Massachusetts-based Tremeau must raise $25 million or more to pay for testing in hemophilia patients. Then the results must be good enough for FDA approval.

In the U.S., just over 20,000 people have hemophilia, an inherited disorder that leaves them without key proteins in the blood needed for clotting. The slightest injury can trigger uncontrolled internal bleeding. Since the 1990s, most patients have been getting medicine that limits but doesn't prevent all bleeding episodes. Blood buildup in the joints can damage them and cause pain.

"Without other options, opioids are often the next step" after Tylenol, sometimes at high doses, said Dr. Stacy Croteau of the Boston Hemophilia Center, who is a paid consultant for Tremeau. "Rofecoxib would hopefully allow us to reduce use of opioids."

Meanwhile, Tremeau is deciding on the drug's brand name. Sippy said the Vioxx name, no longer protected by trademark, might scare some people, while others would remember its effectiveness.

"We haven't excluded it," he said.

Explore further: Merck pays $830 M to settle class-action case over Vioxx

Related Stories

Merck pays $830 M to settle class-action case over Vioxx

January 15, 2016
The drugmaker Merck is paying $830 million to resolve a federal class-action lawsuit involving shareholders and the painkiller Vioxx, which was pulled from the market years ago over safety concerns.

Merck will pay $950M to settle Vioxx investigation

November 22, 2011
(AP) -- The Department of Justice said Tuesday that drugmaker Merck will pay $950 million to resolve investigations into its marketing of the painkiller Vioxx.

FDA OKs new therapy for some hemophilia patients

November 16, 2017
U.S. regulators have approved the first new treatment in nearly two decades to prevent internal bleeding in certain patients with hemophilia, an inherited blood-clotting disorder.

Study finds workers fare worse when popular medications leave the market

September 29, 2017
A little pill can have a big effect on worker absenteeism, according to a new study from the University of Georgia's Terry College of Business.

Recommended for you

Opioid abuse leads to heroin use and a hepatitis C epidemic, researcher says

February 22, 2018
Heroin is worse than other drugs because people inject it much sooner, potentially resulting in increased risk of injection-related epidemics such as hepatitis C and HIV, a Keck School of Medicine of USC study shows.

Opioid addiction treatment behind bars reduced post-incarceration overdose deaths in RI

February 14, 2018
A treatment program for opioid addiction launched by the Rhode Island Department of Corrections was associated with a significant drop in post-incarceration drug overdose deaths and contributed to an overall drop in overdose ...

Heroin vaccine blocks lethal overdose

February 14, 2018
Scientists at The Scripps Research Institute (TSRI) have achieved a major milestone toward designing a safe and effective vaccine to both treat heroin addiction and block lethal overdose of the drug. Their research, published ...

Study shows NIH spent >$100 billion on basic science for new medicines

February 12, 2018
Federally funded research contributed to the science underlying all new medicines approved by the FDA over the past six years, according to a new study by Bentley University.

Opioid use increases risk of serious infections

February 12, 2018
Opioid users have a significantly increased risk of infections severe enough to require treatment at the hospital, such as pneumonia and meningitis, as compared to people who don't use opioids.

Placebo pills prescribed honestly help cancer survivors manage symptoms

February 9, 2018
Long after cancer treatment ends, many continue to deal with one particular symptom that refuses to go away: fatigue. In a new study, researchers at the University of Alabama at Birmingham and Harvard Medical School have ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.